CNTB - Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma | Benzinga
- Rademikibart treatment significantly improved lung function at Week 12; improvements were observed as early as Week 1 and sustained through Week 24
- Significant improvement in patient-reported asthma control occurred early and was sustained through Week 24
- End of Phase 2 (EoP2) meeting is scheduled with the U.S. Food and Drug Administration (FDA) for Q2 2024
SAN DIEGO, CA and TAICANG, China, May 22, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today that Edward Kerwin, M.D. presented a late-breaking poster presentation on the positive results from the rademikibart global Phase 2b trial in patients with moderate-to-severe asthma at the American Thoracic Society (ATS) 2024 International Conference, taking place May 17-22, 2024 in San Diego, CA.
"We are excited Dr. Kerwin shared the highly compelling results of our global Phase 2b study in asthma showing clinically meaningful and sustained improvement in lung function and asthma control with pulmonary experts at this year's meeting," commented Zheng Wei, Ph.D., Co-Founder and CEO of Connect Biopharma. "We are preparing for the End-of-Phase 2 meeting with the FDA for asthma in Q2 2024, and look forward to providing an update on next steps following the completion of this important meeting."
The presentation, titled "Improved Lung Function and Asthma Control Observed with Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma (CBP-201-WW002)", highlighted results from the Phase 2b trial announced in December 2023 that showed that both doses of rademikibart led to significant improvements in pre-bronchodilator (BD) forced expiratory volume over one second (FEV1) ...